<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534634</url>
  </required_header>
  <id_info>
    <org_study_id>IFN-α+CAR-T</org_study_id>
    <nct_id>NCT04534634</nct_id>
  </id_info>
  <brief_title>Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）</brief_title>
  <official_title>An Open-label, Phase 2, Single-Center Study to Assess the Efficacy and Safety of Interferon-α Combined With Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T&#xD;
      cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, single-center study. The patients will receive IFN-α combined with&#xD;
      infusion of CAR T-cells in R/R B-ALL patients. The study participation will be 5 years&#xD;
      including treatment and follow-up periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR includes CR, CRi, MLFS and PR. Complete remission (CR)：Bone marrow blasts &lt;5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0x 10^9/L; platelet count &gt;100x10^9/L. CR with incomplete hematologic recovery (CRi)：All CR criteria except for residual neutropenia (&lt;1.0x10^9/L) or thrombocytopenia (&lt;100x10^9/L). Morphologic leukemia-free state (MLFS): Bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>time from enrollment to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival (LFS)</measure>
    <time_frame>2 years</time_frame>
    <description>time from enrollment to the date of primary refractory disease, or relapse from CR, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse(CIR)</measure>
    <time_frame>2 years</time_frame>
    <description>time from the date of achievement of a remission until the date of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of CAR-T cells in patients</measure>
    <time_frame>2 years</time_frame>
    <description>the time of CAR-T cells' persistence in blood and the copies of CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>adverse events are evaluated with CTCAE V5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFN-α combined with CAR T-cells therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CAR T-cells therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>IFN-α combined with CAR-T cell therapy</intervention_name>
    <description>Adults: 14 daily intramuscular injections 300 million IU of Interferon-α for a 28-day cycle.&#xD;
Children: 14 daily intramuscular injections 200mg/m^2 of Interferon-α for a 28-day cycle.&#xD;
CAR T cell: (1-2)×10^7/kg, intravenously infusion.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>CAR-T cell therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed refractory and relapsed acute B-lymphoblastic leukemia.&#xD;
&#xD;
          2. Age 12-65.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) score 0-2.&#xD;
&#xD;
          4. Target on leukemia is &gt;20% positive detected with flowcytometry.&#xD;
&#xD;
          5. Patients with left ventricular ejection fraction ≥ 0.5 by echocardiography or grade&#xD;
             I/II cardiovascular dysfunction according to the New York Heart Association&#xD;
             Classification.&#xD;
&#xD;
        5.Patients with aspartate aminotransferase or glutamic-pyruvic transaminase &gt; 3x upper&#xD;
        limit of normal or bilirubin &gt; 2.0 mg/dL.&#xD;
&#xD;
        6.No other immunotherapy was received within 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are pregnant or lactating.&#xD;
&#xD;
          2. Patients with congenital immunodeficiency.&#xD;
&#xD;
          3. Patients with central nervous system leukemia.&#xD;
&#xD;
          4. Patients with uncontrolled active infection.&#xD;
&#xD;
          5. Patients with active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          6. Patients with HIV infection.&#xD;
&#xD;
          7. Patients with atrial or venous thrombosis or embolism.&#xD;
&#xD;
          8. Patients with myo-infarction or severe arrythmia in the recent 6 months.&#xD;
&#xD;
          9. Other comorbidities that investigators considered not suitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaowen tang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiaowen tang, Ph.D</last_name>
    <phone>1391353826</phone>
    <email>xwtang1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>depei wu, Ph.D</last_name>
    <phone>86-0512677801856</phone>
    <email>drwudepei@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaowen tang, doctor</last_name>
      <phone>13913538266</phone>
      <email>xwtang1020@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Xiaowen Tang</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>IFN-α, CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

